The present study was designed to evaluate the therapeutic activity of neoadjuvant metformin with respect to Ki67 on sequential core biopsies obtained from patients belonging to the ITT population of the METTEN trial (Figure 1), which included all randomly assigned HER2-positive BC patients who received at least one dose of study medication (n = 79; Table 1). This evidence concerns the gene ERBB2 and breast cancer.